奥密克戎后血液透析患者SARS-CoV-2免疫的纵向特征
这项多中心观察性队列随访55例社区血液透析患者50周,多数已接种至少2剂COVID-19疫苗,发现中和抗体未随时间升高且低于三剂疫苗健康对照,仅56%在BA.1/2波后对Spike有阳性T细胞反应,提示原有疫苗和感染不足以诱导可靠免疫。
要点
- 血液透析患者中和抗体水平低于三剂疫苗健康对照。
- BA.1/2波后仅56%血液透析患者有Spike特异性T细胞阳性反应。
- 既往COVID-19仅使抗体反应趋势升高,T细胞反应无差异。
核心结论
- 原有疫苗配方和既往感染不足以在血液透析患者中诱导可靠的SARS-CoV-2免疫应答。
主要发现
- 中和活性未随时间增加,血液透析患者中和水平低于三剂疫苗接种的健康对照。
- BA.1/2波后仅56%的血液透析患者对Spike蛋白有阳性T细胞反应。
- 末次访视时抗体与细胞反应一致者仅34.5%。
- 既往COVID-19者抗体反应趋势更高,但Spike特异性T细胞反应无差异。
临床怎么用
- 提示应继续更新年度COVID-19疫苗并坚持基于传播的防护措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Individuals receiving hemodialysis (HD) are at risk for severe COVID-19 and have attenuated responses to COVID-19 vaccines. Evolution of immunity and risk for subsequent infection with additional vaccinations and infections in this population is poorly understood. METHODS: An observational multicenter cohort of 55 patients receiving HD in community HD centers, majority (85%) with at least 2 doses of COVID-19 vaccine (56% female, age [median; interquartile range, IQR] of 67, [58.0-74.0] years), was followed-up with for 50 weeks between December, 2021 and April, 2023 and collected blood samples at enrollment, 8 weeks, and 24 weeks thereafter. Anti-SARS-CoV-2 IgG and ACE2 inhibition (surrogate neutralization) against ancestral, Delta, and Omicron subvariants was measured. T-cell responses to Spike and Mucleocapsid proteins were measured via enzyme-linked immunosorbent spot. Changes in antibody and T cell responses were assessed by paired Wilcoxon rank-sum testing and Fisher exact testing. Antibody responses were compared to thrice vaccinated healthy controls (HCs) as a benchmark for what optimal responses could have been in the early Omicron period. RESULTS: Neutralization did not increase over time, and HD participants had lower neutralization than HCs. Only 56% of HD participants had a positive T cell response to spike after the BA.1/2 wave. Antibody and cellular responses were concordant in only 34.5% at final visit. Antibody responses trended higher among those with prior COVID-19, but spike-specific T cell responses did not vary. CONCLUSIONS: Original vaccine formulations and previous infection are insufficient to induce reliable SARS-CoV-2 responses in individuals on HD, suggesting that updated annual COVID-19 vaccines and transmission-based precautions remain critical in this population.
引用
- Karaba AH, Xue J, Johnston TS, et al. Longitudinal Characterization of SARS-CoV-2 Immunity in Hemodialysis Patients Post Omicron. Kidney Int Rep. 2024. PMID: 39990910. doi:10.1016/j.ekir.2024.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。